Vanda Pharmaceuticals Inc. (VNDA), a global biopharmaceutical company with a robust commercial portfolio of 4 approved drugs, faces a near-term regulatory catalyst expected next month, which could have a significant impact on its long-term growth prospects.
The company's investigational drug Bysanti, proposed for the treatment of adults with acute bipolar I disorder and schizophrenia, is under FDA review with a decision expected on February 21, 2026. Bysanti belongs to the class of atypical antipsychotic drugs and is designed to interact with a host of neurotransmitter receptors in the brain, including the alpha-adrenergic receptor, serotonin receptors and dopamine receptors to achieve its therapeutic effect.
For comments and feedback: editorial@rttnews.com